Literature DB >> 16022164

Statistical consideration of adaptive methods in clinical development.

Shein-Chung Chow1, Mark Chang, Annpey Pong.   

Abstract

In recent years, the use of adaptive methods in clinical development based on accrued data has become very popular due to its flexibility in modifying trial procedures and/or statistical procedures of on-going clinical trials. However, it is a concern that the actual patient population after the modifications could deviate from the originally targeted patient population. Major modifications of trial procedures and/or statistical procedures of on-going trials may result in a totally different trial, which is unable to address the scientific/medical questions that the trial intends to answer.

Entities:  

Mesh:

Year:  2005        PMID: 16022164     DOI: 10.1081/BIP-200062277

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  23 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Confounding due to changing background risk in adaptively randomized trials.

Authors:  Ari M Lipsky; Sander Greenland
Journal:  Clin Trials       Date:  2011-05-24       Impact factor: 2.486

3.  Rethinking Phase II Clinical Trial Design in Heart Failure.

Authors:  Kory J Lavine; Douglas L Mann
Journal:  Clin Investig (Lond)       Date:  2013-01-01

4.  A Bayesian adaptive design with biomarkers for targeted therapies.

Authors:  Jens C Eickhoff; KyungMann Kim; Jason Beach; Jill M Kolesar; Jason R Gee
Journal:  Clin Trials       Date:  2010-06-22       Impact factor: 2.486

5.  Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor.

Authors:  Wenqing Li; Ming-Hui Chen; Xiaojing Wangy; Dipak K Dey
Journal:  Stat Biosci       Date:  2017-07-06

Review 6.  Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Adnan I Qureshi; Iryna Lobanova; Wei Huang; Muhammad F Ishfaq; Joseph P Broderick; Christy N Cassarly; Renee H Martin; R Loch Macdonald; Jose I Suarez
Journal:  Neurocrit Care       Date:  2021-12-23       Impact factor: 3.210

7.  Adaptive design clinical trials: Methodology, challenges and prospect.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

8.  Benefits, challenges and obstacles of adaptive clinical trial designs.

Authors:  Shein-Chung Chow; Ralph Corey
Journal:  Orphanet J Rare Dis       Date:  2011-11-30       Impact factor: 4.123

9.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

10.  Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group.

Authors:  Athimalaipet V Ramanan; Neena Modi; Saskia N de Wildt
Journal:  Pediatr Res       Date:  2021-06-07       Impact factor: 3.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.